

Edwards PASCAL Transcatheter Valve Repair System CLASP – 30 Day Multicenter Trial Results¹


A Therapy Dedicated to Effective MR Reduction

Clinically and statistically significant improvements in 30 days


Study Design: Multicenter, multinational, prospective, single-arm study

Total Patients: 62	FMR: 56%
NYHA Class III/IV: 51.6%	DMR: 36%
Mean age: 76.5 years	Mixed etiology: 8%


Significant Reduction in MR Severity




Impressive functional improvements



Meaningful increase in exercise capacity



Improved quality of life



1. Lim DS, Kar S, Spargias K, et al. Transcatheter Valve Repair for Patients With Mitral Regurgitation: 30-Day Results of the CLASP Study. JACC Cardiovasc Interv. 2019;12(14):1369-1378.

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, and PASCAL are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2019 Edwards Lifesciences Corporation. All rights reserved. E9894/07-19/TMTT

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com

